Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 7/20 | 0.33 |
| ▸ | CHRM1 known ✓ | P11229 | 7/20 | 0.33 |
| ▸ | CHRM3 known ✓ | P20309 | 6/20 | 0.31 |
| ▸ | CHRM4 known ✓ | P08173 | 5/20 | 0.31 |
| ▸ | CHRM5 known ✓ | P08912 | 5/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL1179587 | 1.00 | CHRM2 (0.33) | CHRM2CHRM1KCNH2LMNASLC6A3 | |
| SCHEMBL523789 | 0.99 | CHRM2 (0.33) | CHRM2CHRM1KCNH2LMNASLC6A3 | |
| SCHEMBL523790 | 0.99 | CHRM2 (0.33) | CHRM2CHRM1KCNH2LMNASLC6A3 | |
| SCHEMBL4743333 | 0.98 | LMNA (0.33) | CHRM2CHRM1KCNH2LMNASLC6A3 | |
| SCHEMBL1180205 | 0.95 | TACR1 (0.33) | CHRM2CHRM1KCNH2LMNASLC6A3 | |
| SCHEMBL1109929 | 0.95 | TACR1 (0.33) | CHRM2CHRM1KCNH2LMNASLC6A3 | |
| SCHEMBL1109925 | 0.94 | LMNA (0.32) | CHRM2CHRM1KCNH2LMNASLC6A3 | |
| SCHEMBL4741997 | 0.92 | CHRM1 (0.33) | CHRM2CHRM1KCNH2LMNASLC6A3 | |
| SCHEMBL4741995 | 0.92 | CHRM1 (0.33) | CHRM2CHRM1KCNH2LMNASLC6A3 | |
| Bromide SCHEMBL1179154 | 0.91 | CHRM3 (0.37) | CHRM2CHRM1KCNH2LMNASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046191-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ARGENTA DISCOVERY LTD. (GB) | 2011-02-24 | — | — | US | disclosed |
| EP-2124941-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | Argenta Discovery Limited (GB) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008096136-A1 | COMBINATIONS WITH A MUSCARINIC RECEPTOR ANTAGONIST | ARGENTA DISCOVERY LTD (GB) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008096126-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ARGENTA DISCOVERY LTD (GB) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046191-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ADRB2, ADRB1, ADRA2A | CHRM2 8/4885CHRM1 21/4885CHRM3 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.